# **Estimating contamination effects on measured** trial results in TB active case finding cluster randomised trials

Kate E. LeGrand<sup>1</sup>, Rebecca Clark<sup>1</sup>, Palwasha Khan<sup>1,2</sup>, Richard White<sup>1</sup>, Nicky McCreesh<sup>1</sup>

<sup>1</sup>TB Modelling Group, TB Centre, London School of Hygiene and Tropical Medicine, London, UK; <sup>2</sup> Africa Health Research Institute, KwaZulu-Natal, South Africa

#### Background

#### Cluster randomised trials have shown mixed results with many lacking population-level reductions in TB.

Participant **mobility** and interactions between study clusters or the general population can introduce contamination, which may contribute to these negative trial results. Contamination can dilute the effects of the intervention, resulting in an **underestimation** of its true impact.<sup>1</sup>

The influence of contamination is important for understanding trial results and can play a role in **optimising future study design and analysis**.

## Contamination pathways



#### **Transmission model structure**

#### Mathematical models can be used to simulate transmission and intervention delivery scenarios.

To evaluate the **impact of contamination** in a simulated active case finding cluster randomised trial, we developed a dynamic compartmental model of TB natural history. Building upon established models,<sup>5,6</sup> this model incorporates HIV and ART status and our findings from the systematic review of TB cluster RCTs<sup>2</sup> and the social contact survey<sup>4</sup> to inform the ACF trial design and contamination parameters.

#### Natural history







## **Systematic review of TB cluster RCTs<sup>2</sup>**

Screening	Included trials	Contamination
<ul> <li>1,039 titles/abstracts</li> <li>173 full text reports</li> <li>20 reports from 7 trials</li> </ul> <u>Interventions</u> <ul> <li>Active and enhanced</li> </ul>	<ul> <li>ACT3</li> <li>DETECTB</li> <li>Greenland</li> <li>PopART/TREATS</li> <li>SEARCH/SEARCH-TB</li> <li>Thibela TB</li> </ul>	<ul> <li>Facilitators</li> <li>High mobility</li> <li>Small cluster sizes</li> <li>Workforce turnover</li> <li>Social mixing</li> </ul>
<ul> <li>case finding</li> <li>TB preventive treatment</li> <li>HIV-TB test and treat</li> </ul>	• ZAMSTAR	<ul><li><u>Mitigators</u></li><li>Geographic isolation</li><li>Fried egg design</li></ul>

## Social contact patterns

## Identifying local contact patterns is crucial.

Recent molecular studies in high burden settings have shown that over 80% of Mtb transmission occurs outside the home.<sup>3</sup> To better understand transmission dynamics, we analyzed data from a social contact survey conducted in urban, peri-urban, and rural communities in South Africa.<sup>4</sup>

Contact hours were estimated in three settings: within the home, outside the home, and outside the community. Household contact was excluded in the second and third settings. The communities were considered intervention clusters in the third setting, and contact outside the community served as a measure of **mobility** to assess for potential contamination in a cluster RCT.

Our analysis showed **substantial heterogeneity** in the proportion of contact occurring outside the community.

Proportion of contact hours inside and outside the community



## **Intervention scenarios**

Three ACF delivery scenarios will be simulated: 1) Baseline, 2) Programme, and 3) a cluster RCT with varying levels of contamination. The results from the scenarios will be compared to determine the extent that contamination may bias the measured intervention effect.









Baseline No ACF

Programme All receive ACF

**Cluster RCT** Low contamination

**Cluster RCT** High contamination

## **Future applications**

#### Improvements in trial design and reporting may reduce contamination and improve results.

By understanding local contact and movement patterns, policymakers and public health practitioners can develop more effective and equitable strategies to end TB, especially in high burden settings.

- Hayes & Moulton, 2017 LeGrand et al. *I/TLD* 2025 2.
- Verver et al. Lancet 2004
- LeGrand et al. *medRxiv* 2025 Clark et al. Lancet Global Health 2023 5. Sumner et al. Vaccine 2024 6.

Improving Health Worldwide • www.lshtm.ac.uk

